Alliances centered on artificial intelligence and machine learning (AI/ML) applications have become ubiquitous in the biopharmaceutical sector in recent years and are projected to accelerate. But a recent analysis by S&P Global warns that with their deep pockets for business development, big pharmas could establish enduring advantages over smaller competitors via significant investments in AI/ML.
AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
